ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP25-25 MHCP Pharmacy Benefit Exclusion for Datroway®, Frindovyx™, Kebilidi™ and Niktimvo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 12, 2025
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 991 - 1000 လၢ 4884 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP24-25 Commercial Pharmacy Benefit Exclusion for Octreotide Kit, Sandostatin® Kit LAR, and Signifor® LAR injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 12, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP23-25 Commercial Pharmacy Benefit Exclusion for Kebilidi™, Niktimvo™, Steqeyma® and Yesintek™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 12, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP22-25 Provider Press: Q1 2025
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 12, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP21-25 Appropriate Use of Modifier -25
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 12, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P39-25 New Medical and Behavioral Health Policy Management Updates, Effective September 1, 2025
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2025